Norges Bank Invests $2.16 Billion in Amgen Inc. $AMGN

Posted by Francis Steltz on May 30th, 2026

Norges Bank purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 6,611,965 shares of the medical research company’s stock, valued at approximately $2,164,162,000.

Other institutional investors have also made changes to their positions in the company. Dogwood Wealth Management LLC raised its stake in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares in the last quarter. Anfield Capital Management LLC increased its position in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Board of the Pension Protection Fund bought a new position in Amgen in the 4th quarter worth approximately $26,000. Manning & Napier Advisors LLC increased its position in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new stake in shares of Amgen during the 4th quarter worth approximately $33,000. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

Shares of AMGN stock opened at $336.79 on Friday. The stock’s fifty day simple moving average is $342.53 and its 200 day simple moving average is $345.33. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The firm has a market cap of $181.77 billion, a price-to-earnings ratio of 23.44, a P/E/G ratio of 3.38 and a beta of 0.44. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts expect that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 3.0%. Amgen’s payout ratio is currently 70.15%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Leerink Partners reissued a “market perform” rating and set a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. Deutsche Bank Aktiengesellschaft lifted their price objective on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Morgan Stanley set a $332.00 price objective on Amgen in a report on Friday, May 1st. Finally, Jefferies Financial Group assumed coverage on Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $355.19.

Read Our Latest Stock Report on Amgen

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Amgen Company Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.